Edition:
United States

Insmed Inc (INSM.OQ)

INSM.OQ on NASDAQ Stock Exchange Global Select Market

30.41USD
2:16pm EST
Change (% chg)

$0.71 (+2.39%)
Prev Close
$29.70
Open
$29.92
Day's High
$30.59
Day's Low
$29.39
Volume
91,917
Avg. Vol
346,480
52-wk High
$32.84
52-wk Low
$11.49

Latest Key Developments (Source: Significant Developments)

Insmed Q3 loss per share $0.69
Thursday, 2 Nov 2017 07:30am EDT 

Nov 2 (Reuters) - Insmed Inc :Insmed reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.69.Q3 earnings per share view $-0.69 -- Thomson Reuters I/B/E/S.  Full Article

Insmed announces proposed public offering of common stock
Tuesday, 5 Sep 2017 04:01pm EDT 

Sept 6 (Reuters) - Insmed Inc :Insmed announces proposed public offering of common stock.Insmed Inc - ‍Has commenced an underwritten public offering of $250 million of shares of its common stock​.Insmed - Intends to use net proceeds from offering to fund ongoing and future clinical development of amikacin liposome inhalation suspension, among the others.  Full Article

Insmed announces positive top-line results from phase 3 convert study of ALIS
Tuesday, 5 Sep 2017 07:00am EDT 

Sept 5 (Reuters) - Insmed Inc :Insmed announces positive top-line results from phase 3 convert study of ALIS (amikacin liposome inhalation suspension) in adult patients with treatment-refractory nontuberculous mycobacterial (NTM) lung disease caused by mycobacterium avium complex (MAC).Study met primary endpoint of culture conversion (p< 0.0001)​.Positive top-line results from global phase 3 controlled study in patients with NTM, a rare, progressive, destructive lung infection​.Company plans to pursue accelerated approval and request priority review​.Plans to pursue accelerated approval of ALIS under subpart H based on data from convert study, which will be reviewed by division of anti-infective products​.Company also reported top-line data for several secondary endpoints as of 6-month timepoint​.Top-line data for 6-minute walk test indicates no statistically significant difference between patients in two arms​.Company is continuing its analysis of impact of conversion on a variety of other clinical measures​.  Full Article

Insmed reports Q2 loss per share $0.72
Thursday, 3 Aug 2017 07:30am EDT 

Aug 3 (Reuters) - Insmed Inc ::Insmed reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.72.Q2 earnings per share view $-0.63 -- Thomson Reuters I/B/E/S.Insmed Inc - ‍on track to report top-line results from phase 3 convert study in September plus or minus one month​.Insmed Inc - ‍plan to initiate enrollment of phase 2 dose-ranging study of INS1007 in non-cystic fibrosis (non-CF) bronchiectasis in H2 2017​.  Full Article

Insmed Inc files for potential stock shelf offering
Friday, 19 May 2017 04:35pm EDT 

May 19 (Reuters) - Insmed Inc :Files for potential stock shelf offering; size not disclosed - SEC filing.  Full Article

Insmed appoints Paolo Tombesi CFO, effective June 1, 2017
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - Insmed Inc :Insmed announces key additions to its executive management team.Insmed inc says appointment of Paolo Tombesi as chief financial officer, effective June 1, 2017.Insmed inc says additionally, Eugene Sullivan has been appointed to newly created role of chief product strategy officer.  Full Article

Insmed reports Q1 loss per share $0.60
Wednesday, 3 May 2017 08:02am EDT 

May 3 (Reuters) - Insmed Inc : :Insmed reports first quarter 2017 financial results and provides business update.Q1 loss per share $0.60.Q1 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.Insmed inc- continues to expect its cash-based operating expenses to be in range of $67 million to $77 million for first half of 2017.  Full Article

Insmed announces worldwide license agreement with AstraZeneca for oral DPP1 inhibitor
Wednesday, 5 Oct 2016 06:55am EDT 

Insmed Inc : Insmed will pay AstraZeneca an upfront payment of $30 million . Agreement provides AstraZeneca with option to negotiate a future agreement with Insmed for commercialization of AZD7986/ins1007 . Continue to expect patient enrollment in phase 3 study of Arikayce to conclude later this year and to report top line data in 2017 . Confirms its cash operating expense guidance for second half of 2016 of $62 million to $72 million . In a phase 1 study of healthy volunteers AZD7986 was well tolerated . Says AstraZeneca will be eligible to receive future payments totaling $120 mln in future clinical, regulatory, and sales-related milestones .Confirms its cash operating expense guidance for second half of 2016 of $62 to $72 million..  Full Article

Insmed Q2 loss per share $0.59
Thursday, 4 Aug 2016 08:02am EDT 

Insmed Inc : Q2 loss per share $0.59 . Insmed reports second quarter 2016 financial results .Q2 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S.  Full Article

Insmed says withdraws marketing application for Arikayce in Europe
Wednesday, 8 Jun 2016 05:14pm EDT 

Insmed Inc : Insmed Inc - announces withdrawal of marketing authorization application for arikayce in europe . Insmed Inc says marketing application filing was based on data from co's completed phase 2 study . Insmed Inc - During may 2016 chmp meeting, the panel indicated that phase 2 study did not provide a sufficient amount of evidence to support an approval .Insmed inc says it intends to resubmit its application for arikayce when clinical data from its ongoing global phase 3 study are available..  Full Article

BRIEF-Insmed Q3 loss per share $0.69

* Insmed reports third quarter 2017 financial results and provides business update